KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Current Liabilities: 2017-2025

Historic Total Current Liabilities for Aquestive Therapeutics (AQST) over the last 8 years, with Sep 2025 value amounting to $25.6 million.

  • Aquestive Therapeutics' Total Current Liabilities rose 68.78% to $25.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $25.6 million, marking a year-over-year increase of 68.78%. This contributed to the annual value of $18.9 million for FY2024, which is 3.04% up from last year.
  • As of Q3 2025, Aquestive Therapeutics' Total Current Liabilities stood at $25.6 million, which was up 10.45% from $23.2 million recorded in Q2 2025.
  • Aquestive Therapeutics' 5-year Total Current Liabilities high stood at $40.4 million for Q1 2023, and its period low was $13.9 million during Q2 2024.
  • Moreover, its 3-year median value for Total Current Liabilities was $18.9 million (2024), whereas its average is $23.1 million.
  • Per our database at Business Quant, Aquestive Therapeutics' Total Current Liabilities spiked by 79.97% in 2022 and then tumbled by 64.05% in 2024.
  • Quarterly analysis of 5 years shows Aquestive Therapeutics' Total Current Liabilities stood at $22.0 million in 2021, then surged by 79.97% to $39.5 million in 2022, then tumbled by 53.68% to $18.3 million in 2023, then climbed by 3.04% to $18.9 million in 2024, then surged by 68.78% to $25.6 million in 2025.
  • Its Total Current Liabilities was $25.6 million in Q3 2025, compared to $23.2 million in Q2 2025 and $18.3 million in Q1 2025.